Catalyst Dossier · compiled by CeliA 🧫
Innovation Pharmaceuticals Inc. (IPIX)
Pharmaceutical Preparations · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-25 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Innovation Pharmaceuticals Inc. (IPIX) is a micro-cap pharmaceutical company with a market capitalization of approximately $9 million and a lead asset, F14, in Phase 3 development for post-operative pain. The company maintains an unusually broad pipeline — spanning oncology, neurology, autoimmune disease, and ophthalmology — though the mechanism of action for F14 is undisclosed and financial details including cash, runway, and revenue are unavailable. Several of the pipeline assets appear to be sponsored or partnered trials rather than wholly owned IPIX programs, which materially limits the attributable value.
The catalyst path
- 2026-12-25 (est.)Phase 3 · Gemcitabine hydrochloride and albumin binding paclitaxelimp 9/10
- 2027-02-15 (est.)Phase 2 · GI-108imp 7/10
- 2027-03-31 (est.)Phase 3 · Cenerimodimp 9/10
- 2027-04-15 (est.)Phase 2 · S095018imp 7/10
- 2027-05-01 (est.)Phase 2 · S095035imp 7/10
- 2027-07-15 (est.)Phase 3 · Reference Drugimp 9/10
- 2027-08-15 (est.)Phase 2 · ANO31905imp 7/10
- 2027-08-15 (est.)Phase 2 · S095029imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Standard of Care (SoC) | Phase 2 | COVID-19 |
| Kevetrin | Phase 2 | Ovarian Cancer |
| Brilacidin | Phase 2 | Head and Neck Neoplasms |
| F14 | Phase 3 | Post Operative Pain |
| 400 mg (200 mg BID) | Phase 2 | Chronic Stable Plaque Psoriasis |
| JI-101 | Phase 2 | Advanced Solid Tumors |
| Gemcitabine hydrochloride and albumin binding paclitaxel | Phase 3 | Locally Advanced Pancreatic Cancer |
| SOM3355 100mg BID | Phase 2 | Huntington's Chorea |
| ANO31905 | Phase 2 | Pancreatic Cancer |
| S095018 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) |
| NTI164 | Phase 2 | PANS Pediatric Acute-Onset Neuropsychiatric Syndrome |
| Cenerimod | Phase 3 | Lupus Erythematosus, Systemic |
| GI-108 | Phase 2 | Advanced Solid Tumor |
| THR-184 | Phase 2 | Acute Kidney Injury |
| Selatogrel 8 mg | Phase 2 | Acute Myocardial Infarction |
| temelimab 18 mg/kg | Phase 2 | Multiple Sclerosis |
| Bupivacaine HCl | Phase 2 | Total Knee Replacement |
| GNbAC1 | Phase 2 | Multiple Sclerosis |
| PRS-344/S095012 | Phase 2 | Solid Tumor |
| GI-102 subcutaneous (SC) | Phase 2 | Advanced Solid Tumor |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IPIX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.